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Applying Data-driven Imaging 
Biomarker in Mammography 
for Breast Cancer Screening: 
Preliminary Study
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Ok Hee Woo5 & Chan Wha Lee6
We assessed the feasibility of a data-driven imaging biomarker based on weakly supervised learning 
(DIB; an imaging biomarker derived from large-scale medical image data with deep learning 
technology) in mammography (DIB-MG). A total of 29,107 digital mammograms from five institutions 
(4,339 cancer cases and 24,768 normal cases) were included. After matching patients’ age, breast 
density, and equipment, 1,238 and 1,238 cases were chosen as validation and test sets, respectively, 
and the remainder were used for training. The core algorithm of DIB-MG is a deep convolutional neural 
network; a deep learning algorithm specialized for images. Each sample (case) is an exam composed 
of 4-view images (RCC, RMLO, LCC, and LMLO). For each case in a training set, the cancer probability 
inferred from DIB-MG is compared with the per-case ground-truth label. Then the model parameters in 
DIB-MG are updated based on the error between the prediction and the ground-truth. At the operating 
point (threshold) of 0.5, sensitivity was 75.6% and 76.1% when specificity was 90.2% and 88.5%, 
and AUC was 0.903 and 0.906 for the validation and test sets, respectively. This research showed the 
potential of DIB-MG as a screening tool for breast cancer.
Mammography is widely recommended for breast cancer screening, although the starting age and screening 
interval for its application have been debated1–5. Screening mammography is recommended as it has a sensitivity 
over 85% and a specificity over 90%6; however, performance varies according to the radiologists’ experience or 
working area (academic vs nonacademic, general vs specific)7–9. Computer-aided detection (CAD) acts as an 
automated second reader by marking potentially suspicious spots for radiologists to review and several early 
reports emphasized that this could improve mammographic sensitivity10–13, with 74% of all screening mammo-
grams in the Medicare population being interpreted with CAD by 200814,15.
Since the wide introduction of CAD into clinics, radiologists using this technology have complained of a high 
number of false-positive markers and several recent studies reported that CAD does not improve the diagnostic 
accuracy of mammography16,17. This was somewhat expected. Most learning algorithms including CAD are based 
on pre-defined hand-crafted features, so they are task-specific, a-priori knowledge based, which causes a large 
bias towards how humans think the task is performed18. Whereas in new algorithms including deep learning, the 
research has shifted from rule-based, problem specific solutions to increasingly generic, problem agnostic meth-
ods19–21. This is possible due to the backup of big data, increased computing power and sophisticated algorithms.
The algorithm developed in this study was named data-driven imaging biomarker (DIB; an imaging bio-
marker derived from large-scale medical image data by using deep learning technology) in mammography 
(DIB-MG). The basic learning strategy of DIB-MG is weakly supervised learning. Unlike the conventional CAD 
designs, DIB-MG learns radiologic features from large scale images without any human annotations. So, the 
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purpose of our study was to assess the feasibility of DIB in mammography (DIB-MG) and to evaluate its potential 
for the detection of breast cancer.
Materials and Methods
Data collection. Five institutions (all tertiary referral centers) formed a consortium for the imaging data-
base. All study protocols were approved by the institutional review board of Yonsei University Health System 
(approval number: 1-2016-0001) and the requirement for informed consent was waived. All experiments were 
conducted in accordance with the Good Clinical Practice guidelines. For algorithm development, digital mam-
mography images were retrospectively obtained from PACS. We included women with four views of digital mam-
mograms. Exclusion criteria were as follows. 1) Women with previous surgery for breast cancer, 2) Women with 
previous surgery for benign breast disease within 2 years, 3) Women with mammoplastic bag, 4) Women with 
mammographic clip or marker. All cancer cases were confirmed by pathology and all normal cases were defined 
as BI-RADS category 1 (negative) without malignancy development during at least 2 years of follow-up. Both 
screening and diagnostic mammograms were included. This study was solely focused on whether our algorithm 
could discriminate cancer from normal cases, so presumed benign cases (BI-RADS categories 2, 3, 4, and 5 
without cancer) were not included. Accordingly, 29,107 digital mammogram sets were obtained, in which there 
were 4,339 cancer cases and 24,768 normal cases. All images in the data sets were recorded by radiologists for 
breast density, cancer type (invasive vs noninvasive), features (mass, mass with microcalcifications, asymmetry 
or focal asymmetry, distortion, microcalcification only, etc.) and size of the invasive cancer. For cancers showing 
mass with microcalcifications, both mass and microcalcifications were recorded as features. Breast density was 
recorded using BI-RADS standard terminology of almost entire fat (A), scattered fibroglandular densities (B), 
heterogeneous dense (C), and extremely dense (D)6.
Data sets. In 4,339 cancer cases, training, validation and test sets were randomly selected with a ratio of 
5:1:1 (3,101/619/619). Each dataset was evenly distributed in terms of patients’ age, breast density, and manufac-
turer, and cancer type, feature, and size in order to remove selection bias between training, validation and test 
sets (Table 1). Predominant features of cancer were mass (n = 2,366) or microcalcifications (n = 1,962), so other 
features (asymmetry for focal asymmetry (n = 463), distortion (n = 100)) were not controlled in the data sets.
In 24,768 normal cases, the same number of validation (n = 619) and test (n = 619) cases were randomly 
selected, and the rest were used for training. For normal cases, each partition of the dataset was evenly distributed 
in terms of patients’ age, breast density, and manufacturer in order to remove selection bias (Table 2).
Development of the Algorithm. Deep convolutional neural network (DCNN) is a deep learning algo-
rithm specialized for images22. Each convolutional layer extracts features hierarchically (layer-by-layer) to 
abstract semantics from the raw input images. DIB-MG is implemented based on a residual network (ResNet)23, 
the state-of-the-art DCNN model for image recognition. Figure 1 shows the overall architecture of DIB-MG. It 
Train (n = 3101)
Validation 
(n = 619) Test (n = 619) P value
Density 0.7843
   almost entire fat 196 (6.32) 32 (5.2) 31 (5.0)
   scattered fibroglandular densities 640 (20.6) 136 (22.0) 137 (22.1)
   heterogeneous dense 1555 (50.2) 312 (50.4) 312 (50.4)
   extremely dense 710 (22.9) 139 (22.4) 139 (22.5)
Age 0.9941
   ≥50 1759 (56.7) 350 (56.5) 350 (56.5)
   <50 1342 (43.3) 269 (43.5) 269 (43.5)
Manufacturer 0.9351
   GE 1226 (39.5) 238 (38.5) 251 (40.6)
   Hologic 1032 (33.2) 200 (32.3) 198 (32.0)
   Siemens 843 (27.2) 181 (29.2) 170 (27.4)
Feature
   mass 1688 (54.4) 339 (54.8) 339 (54.8) 0.9806
   non mass 1413 (45.6) 280 (45.2) 280 (45.2)
   calcifications 1402 (45.2) 280 (45.2) 280 (45.2) 0.9999
   non calcifications 1699 (54.8) 339 (54.8) 339 (54.8)
Type 0.2767
   Invasive 2673 (86.2) 542 (87.56) 547 (88.37)
   Noninvasive 428 (13.8) 77 (12.44) 72 (11.63)
Size (invasive) 0.8409
   Size ≥20 1216 (45.5) 254 (46.9) 251 (45.9)
   Size <20 1457 (54.5) 288 (53.1) 296 (54.1)
Table 1. Demographics in cancer cases.
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consists of two initial blocks (init_block), four residual blocks (residual_block), and an aggregation block (aggre-
gate_block). Each residual block includes four consecutive convolution layers with skip connection as described 
in the right-bottom of the Fig. 1 (⊕ is an element-wise addition operator), while the other blocks include a single 
convolution layer. Each block also includes some auxiliary components such as a batch normalization layer (BN: 
normalization of activations within a batch)24, a rectified linear unit (ReLU: a simple mathematical function for 
non-linear activation)22, a max-pooling layer (Pmax: static dimension reduction function for translation-invariant 
feature abstraction)22, and a global-average-pooling (GPavg: average of the entire 2-dimensional input feature 
map)23. Details of the components are well described in the original literatures22–24.
DIB-MG consists of nineteen convolution layers with a two-stage global-average-pooling layer. The former 
eighteen convolution layers extract hierarchical features for cancer classification, while the last convolution layer 
(1 × 1 convolution kernel with filter width 2) generates per-view maps (one for cancer, and the other for nor-
mal cases) via for final DIB construction (Fig. 2). Figure 3 shows an example of DIB as well as ground-truth 
lesions. Since we did not use pixel-level lesion annotation in this experiment, each per-view map generated from 
the last convolution layer (i.e. map generation stage) was converted in a single value to be compared with the 
ground-truth label (biopsy-proven cancer: 1 or normal: 0). So, the final maps were converted into a vector (each 
vector element represents its own class) using the global-average-pooling operation. In the training stage, the 
error between the output vector (y_pred in Fig. 2) and the ground-truth label was propagated backward via 
back-propagation algorithm25, and the model parameters of the entire network were updated based on the prop-
agated errors.
Training Set-up. All the DICOM files are first converted to PNG files considering window_center and win-
dow_width defined in the header of each DICOM, and then the pixel values are normalized to be in the range 
−1.0 to 1.0. Random perturbation of the pixel intensity in terms of constrast (±10%) and brightness (±10%) is 
used every training iteration to overcome the difference in vendor-specific contrast/brightness characteristics. All 
Train (n = 23530) Validation (n = 619) Test (n = 619) P value
Density 0.898
   almost entire fat 837 (3.6) 27 (4.4) 18 (2.9)
   scattered fibroglandular densities 4206 (17.9) 106 (17.1) 115 (18.6)
   heterogeneous dense 16434 (69.8) 432 (69.8) 432 (69.8)
   extremely dense 2053 (8.7) 54 (8.7) 54 (8.7)
Age 0.997
   ≥50 14533 (61.8) 383 (61.9) 383 (61.9)
   <50 8997 (38.2) 236 (38.1) 236 (38.1)
Manufacturer 0.4872
   GE 11526 (49.0) 284 (45.9) 315 (50.9)
   Hologic 10191 (43.3) 282 (45.6) 257 (41.5)
   Siemens 1813 (7.7) 53 (8.6) 47 (7.6)
Table 2. Demographics in normal cases.
Figure 1. Overall architecture – 19 convolutions followed by a global-average-pooling (GPavg).
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the input images are downscaled to 1600 × 1600, i.e. rescaled to 1600 in terms of the longer side and zero-padded 
to be 1600 × 1600 (zero-padded on the left side of RCC/RMLO and the right side of LCC/LMLO).
Initial learning rate 0.001 is decayed by a factor of 5 every 10 epochs until the 30 epochs. Stochastic gradient 
descent (SGD) with momentum 0.9 is used for optimization. Minibatch size is 64 images (16 exams) based on 
eight graphic processing units (GPUs). Weight decay constant 0.0005 is used for regularization. All the experi-
ment is done with TensorFlow26.
Evaluation of the Algorithm. Training proceeds to minimize the prediction error of the entire training set, 
and the final DIB-MG performed best on the validation set is chosen for evaluation on the test set. In an inference 
stage, the final output value of the trained model (y_pred ranging from 0.0 to 1.0) is used to decide whether the 
input case is cancer or not. More specifically, y_pred represents the confidence level of malignancy. This value is 
not exactly equal to the probability of cancer, as cancer cannot be specified as a probability. But it is correlated 
with the cancer probability in real exams. The constructed DIB (class number of per-view maps generated from 
the last convolution layer) includes information on spatial discriminativity. As mentioned before, each map rep-
resents the corresponding class and shows the most discriminative part in terms of the final classification result; 
e.g., if y_pred is 0.9 (cancer probability), then the region with the highest value on the cancer map is the most 
discriminative part in terms of its cancer decision.
Figure 2. Hierarchical feature abstraction, DIB map generation, and cancer probability generation.
Figure 3. DIB example with ground-truth lesion. A 44-year-old woman with invasive ductal carcinoma of the 
right breast. A 22 mm-sized mass was correctly highlighted by DIB. The confidence score for cancer of DIB was 
1.0 and 0.026 for the right and left breast.
www.nature.com/scientificreports/
5SCIENTIfIC REPORTS |  (2018) 8:2762  | DOI:10.1038/s41598-018-21215-1
Statistical Analysis and Performance Comparison. Chi-square tests were used to see whether there 
was any difference in categorical variables between training, validation and test sets. With validation and test sets, 
diagnostic performances were measured. Sensitivity, specificity, and accuracy were compared according to vari-
ous demographics using the chi-square test. For features, logistic regression with the generalized estimating equa-
tion (GEE) method was applied to take into account that some patients had mass with microcalcifications. The 
AUC were compared between the validation and test sets using chi-square statistics. All analyses were conducted 
by a statistician using SAS statistical software (version 9.4; SAS Institute Inc., Cary, NC, USA) and R version 3.3.1 
(R Foundation for Statistical Computing, Vienna, Austria).
Results
At the operating point (threshold) of 0.5, sensitivity was 75.6% and 76.1% when specificity was 90.2% and 88.5%, 
and AUC was 0.903 and 0.906 for the validation and test sets, respectively, with no statistical difference (Table 3). 
Sensitivity and specificity were not statistically significant between age ≥50 and <50, but they were significantly 
different according to the manufacturer (Table 3). In regards to breast density, sensitivity was not affected, how-
ever, specificity and accuracy decreased as breast density increased (Table 4).
In the malignant group (Table 5), sensitivity was better in mass than in calcifications (84.1–86.1% vs 77.5–
77.9%), better in invasive cancer than in non-invasive cancer (77.0–77.9% vs 54.2–59.7%), and better in mass 
≥20 mm than <20 mm (88.5–88.6%, 68.4–71.0%).
Sensitivity (%) Specificity (%) Accuracy (%) AUC
Validation Set 75.6 (468/619) 90.2 (558/619) 82.9 (1026/1238) 0.903
 Age
   ≥50 77.1 (270/350) 91.9 (352/383) 84.9 (622/733) 0.914
   <50 73.6 (198/269) 87.3 (206/236) 80.0 (404/505) 0.882
   p value* 0.310 0.061 0.026 0.080
 Manufacturer
   GE 77.5 (186/240) 91.1 (257/282) 84.9 (443/522) 0.924
   Hologic 63.6 (126/198) 93.3 (265/284) 81.1 (391/482) 0.863
   Siemens 86.2 (156/181) 67.9 (36/53) 82.1 (192/234) 0.861
   p value* <0.0001 <0.0001 0.2704
   Test Set 76.1 (471/619) 88.5 (548/619) 82.3 (1019/1238) 0.906
 Age
   ≥50 76.3 (267/350) 90.1 (345/383) 83.5 (612/733) 0.911
   <50 75.83 (204/269) 86.01 (203/236) 80.6 (407/505) 0.897
   p value* 0.897 0.124 0.189 0.395
 Manufacturer
   GE 74.6 (188/252) 89.1 (229/257) 81.9 (417/509) 0.910
   Hologic 67.0 (132/197) 92.1 (290/315) 82.4 (422/512) 0.880
   Siemens 88.8 (151/170) 61.7 (29/47) 83.0 (180/217) 0.888
   p value* <0.0001 <0.0001 0.943
Table 3. Diagnostic Performances according to age and manufacturer. *chi-square test.
Sensitivity (%) Specificity (%) Accuracy (%) AUC
Validation Set 75.6 (468/619) 90.2 (558/619) 82.9 (1026/1238) 0.903
 Parenchymal density
   A (n = 59) 81.3 (26/32) 100 (27/27) 89.8 (53/59) 0.946
   B (n = 242) 80.9 (110/136) 96.2 (102/106) 87.6 (212/242) 0.950
   C (n = 744) 75.0 (234/312) 90.3 (390/432) 83.9 (624/744) 0.900
   D (n = 193) 70.5 (98/139) 72.2 (39/54) 71.0 (137/193) 0.790
   p value* 0.201 <0.001 <0.001
Test Set 76.1 (471/619) 88.5 (548/619) 82.3 (1019/1238) 0.906
 Parenchymal density
   A (n = 49) 90.3 (28/31) 100 (18/18) 93.88 (46/49) 0.960
   B (n = 252) 75.9 (104/137) 92.17 (106/115) 83.33 (210/252) 0.935
   C (n = 744) 75.6 (236/312) 88.43 (382/432) 83.06 (618/744) 0.899
   D (n = 193) 74.1 (103/139) 77.78 (42/54) 75.13 (145/193) 0.851
   p value* 0.301 <0.061 <0.026
Table 4. Diagnostic Performances according to breast density. *Chi-square test.
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Discussions
This is the first study that applies deep learning algorithms in mammography without pixel-level supervision. Our 
results showed that the AUC values for diagnosing breast cancer using the DIB-MG algorithm were 0.903–0.906, 
which demonstrates that DIB-MG algorithms can be trained with large-scale data sets without pre-defined mam-
mographic features.
Deep learning algorithm in mammography have been previously studied by several researchers. Wang et al. 
reported that breast cancers presenting microcalcifications could be discriminated by deep learning27. They used 
a previously reported computerized segmentation algorithm in order to extract the clustered microcalcifications 
from mammograms28. In their approach, pre-defined microcalcification features obtained from lesion-annotated 
mammograms were used as an input for the unsupervised deep learning model (stacked autoencoder)29. Kooi 
et al. compared state-of-the art mammography CAD systems, relying on manually designed features as well 
as data-driven features using DCNN18. Especially in a deep learning approach, image patches extracted from 
lesion-annotated mammograms were used for training. Becker et al. evaluated the diagnostic performance of 
their deep neural network model for breast cancer detection30. A total 143 histology-proven cancers and 1,003 
normal cases were used for this study, where all the cancer cases of the training dataset were manually annotated 
pixel-wise by radiologists according to descriptions in the radiology report. Compared to the aforementioned 
approaches, we used pure data-driven features from raw mammograms without any lesion annotations, which is 
scalable and practical for future CAD systems.
In previous reports with CAD, sensitivity was higher in microcalcifications than mass31–34, however, in this 
study, sensitivity was better in mass than calcifications. That is due to the difference in data sets. In our data set, 
both screening and diagnostic mammograms were included, in which 45.7% (1721/3762) of invasive carcinomas 
were equal or larger than 2 cm, whereas other studies with CAD included only screening mammograms31–34. 
Further studies using the DIB-MG algorithm on screening data sets should follow.
Our data showed that sensitivity for breast cancer detection was similar for non-dense breasts and dense 
breasts. However, specificity decreased as breast density increased. Eventually, low specificity was directly related 
with increasing false-positives, so we need to develop algorithms increasing specificity in the future.
In our study, diagnostic performance was different according to the manufacturer; sensitivity is the highest 
(88.8%) and specificity is the lowest (61.7%) in Siemens. In each data set (training, validation and test sets), the 
three manufacturers were evenly distributed (roughly 4:3:3 in cancer cases, 5:4:1 in normal cases). However, can-
cer cases were occupied with 27.2–29.2%, compared to 7.6–8.6% in normal cases in Siemens machine. This indi-
cates that the number of cases trained with a certain type of machine can influence the diagnostic performance 
of mammography. This kind of selection bias should be considered in a future study regarding deep learning.
We acknowledge several limitations of our study. First, in this study we included only normal and cancer cases, 
so benign cases need to be included. Also, the dataset should be more expanded. Second, our model does not use 
any pixel-level annotations for training, so there might be errors in predicting the lesion location in examples 
predicted as cancer. It is necessary to confirm whether the lesion location is accurately predicted, and retrain the 
model based on those examples to improve localization performance.
In conclusion, this research showed the potential of DIB-MG as a screening tool for breast cancer. Further 
studies using a large number of high-quality data including benign cases are needed to further investigate its 
feasibility as a screening tool.
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